Adagene Begins Phase 1 Trial Of Muzastotug Plus INCA33890 In MSS Colorectal Cancer; Stock Up
Adagene (ADAG) dosed the first patient in a Phase 1 trial of muzastotug with Incyte's (INCY) INCA33890 for MSS colorectal cancer. The open-label study targets third-line patients. ADAG shares rose 10.47% in pre-market trading to $2.85. The 52-week range is $1.30 to $4.85.
How this was made
The 30-second read
Why it matters
The dosing of the first patient signals that the collaboration with Incyte is progressing on schedule, which can reduce execution risk and attract speculative buying.
Market read
The announcement moved ADAG shares up ~10% pre‑market, indicating immediate market relevance for traders.
What to watch
The partnership with Incyte may provide additional resources but also dilutes Adagene's upside if Incyte takes a larger share of future revenues.
Background
Adagene (ADAG) is a clinical‑stage biotech focused on immuno‑oncology. The Phase 1 study targets microsatellite stable colorectal cancer, a hard‑to‑treat indication.
Ticker impact
Adagene announced the first patient dosed in a Phase 1 trial of its drug muzastotug combined with Incyte's INCA33890 for MSS colorectal cancer.
likely upward pressure as the market prices in the early‑stage trial progress
First‑patient dosing is fresh, material news for a micro‑cap biotech and has already moved the stock up ~10% in pre‑market trading.
Market effects
Early‑stage oncology trial activity may boost interest in the MSS colorectal cancer therapeutic niche.
Primarily U.S. biotech investors; limited broader market effect.
Minimal outside the biotech sector.
Counterpoint
If the trial encounters safety issues, the initial hype could reverse quickly.
Key entities
- CompanyAdagene Inc.
US‑listed biotech developing the anti‑CTLA‑4 SAFEbody muzastotug.
- CompanyIncyte Corp.
Partner sponsoring the trial and providing INCA33890.

